Qi Ying,Chen Dongji,Ma Youguo,Wang Xiaopeng,Dang Youquan,Duan Yunlong,Chen Zhe.Induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with locally advanced pancreatic cancer[J].Chinese Journal of Radiological Medicine and Protection,2014,34(5):355-357
Induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with locally advanced pancreatic cancer
Received:July 11, 2013  
DOI:10.3760/cma.j.issn.0254-5098.2014.05.009
KeyWords:Locally advanced pancreatic cancer  Radiotherapy  Induction chemotherapy
FundProject:
Author NameAffiliationE-mail
Qi Ying Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China  
Chen Dongji Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China cdj999999@126.com 
Ma Youguo Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China  
Wang Xiaopeng Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China  
Dang Youquan Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China  
Duan Yunlong Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China  
Chen Zhe Radiotherapy Department, Wuwei Tumor Hospital of Gansu Province, Wuwei 73000, China  
Hits: 2696
Download times: 2174
Abstract::
      Objective To evaluate the safety and efficacy of induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapywith capecitabine in patients with locally advanced pancreatic cancer (LAPC).Methods A total of 42 patients with locally advanced pancreatic cancer were enrolled.All patients received seven cycles of induction chemotherapy of gemcitabine 1 000 mg/m2, once a week.Concurrent chemoradiotherapy began 1 week after completion of induction chemotherapy.Radiotherapy was delivered with a median dose of 54 Gy (34-64 Gy) with 1.8-2.0 Gy in a fraction.The radiotherapy was combined with capecitabin at a dosage of 825 mg/m2 twice daily, 5 d/week.Results Twenty patients (47.6%) were evaluated as clinical benefit response (CBR).Two cases were observed with complete remission (CR), 8 with partial remission (PR), 27 with stable disease (SD), and 5 with progressive disease (PD).The median overall survival was 10.1 months (range of 4-36 months).The 1-, 2-year overall survival rate was 38.2% and 18.2%, respectively.Myelosuppression was recorded in 20 patients with grades 1-2, and 5 patients with grade 3.Twenty-two patients suffered from grade 1-2 gastrointestinal toxicities, while 4 patients suffered from grade 3.Conclusions The preliminary results showed that induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with LAPC might achieve encouraging efficacy with better tolerance.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:9061926  On-line:0

v
Scan QR Code
&et=486866E8A4A513A643C6FD829AE13DEE55955668432A1CDAD18D60DEB05B24C8659EC5E80F70679B3F16612A2780F62D91B5865795CEDFFAF4846F203E1B3F8CEF669DAD0EF078710132D79CC65317037D57348630CA0A4AB8C1B6163ED057793ED2289FC41D3041C7441F94AAC68BC4F193BCBD6E6FFCCEBA32A2653A0EA8799E49FFE3ACC31E5BB3596C11B8AFB0D27FAFF26009C9A1CE&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=9EAD63ADE6B277ED&aid=3CC66326E61FC91BE02052EC3BB98489&vid=&iid=94C357A881DFC066&sid=26AEEED215BE97D0&eid=FA88DCCE84EA0A56&fileno=20140509&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="9EAD63ADE6B277ED"; var my_aid="3CC66326E61FC91BE02052EC3BB98489";